Molecularly targeted therapies for colorectal cancer: Strategies for implementing translational research in clinical trials

Curr Opin Mol Ther. 2010 Dec;12(6):703-11.


Few breakthroughs in preclinical research have translated into meaningful benefits, either in clinical terms or quality of life, for patients with advanced colorectal cancer, despite important preclinical discoveries regarding aberrant biological pathways associated with disease development and progression. The many reasons for the slow progress are diverse, ranging from the failure to codevelop biomarkers and targeted therapies, the regulatory burdens imposed on academic investigators, and the failure to collect serial tumor biopsies during clinical trials. This review discusses promising translational research that could help reduce the disparity between preclinical discovery and patient benefit, and advocate the concentration of efforts and resources on the most promising therapeutic targets in colorectal cancer, such as EGFR, VEGF and Fcγ receptor.

Publication types

  • Review

MeSH terms

  • Biomarkers, Tumor / genetics
  • Biomarkers, Tumor / metabolism
  • Clinical Trials as Topic / methods*
  • Colorectal Neoplasms / drug therapy*
  • Colorectal Neoplasms / genetics
  • Colorectal Neoplasms / metabolism
  • ErbB Receptors / genetics
  • ErbB Receptors / metabolism
  • Humans
  • Models, Biological
  • Molecular Targeted Therapy / methods*
  • Translational Medical Research / methods*
  • Vascular Endothelial Growth Factor A / genetics
  • Vascular Endothelial Growth Factor A / metabolism


  • Biomarkers, Tumor
  • Vascular Endothelial Growth Factor A
  • ErbB Receptors